

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Astrazeneca : Chronic Heart Failure  Novo-Nordisk : Risk Factors and Prevention  Amarin : Risk Factors and Prevention</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b>  I am a board member of the French Society of Cardiology, and the French Federation of Cardiology</p>
Agewall Stefan	<p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b>  EU Horizon</p>
Back Magnus	<p><b>2024</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Amarin : Risk Factors and Prevention</p>
Boehm Michael	<p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Abbott : Chronic Heart Failure, Hypertension  Amgen : Chronic Heart Failure, Hypertension  Astra Zeneca : Chronic Heart Failure, Hypertension  Bayer : Chronic Heart Failure, Hypertension  Boehringer-Ingelheim : Chronic Heart Failure, Hypertension  Medtronic : Chronic Heart Failure, Hypertension  Novartis : Chronic Heart Failure, Hypertension  Servier : Chronic Heart Failure, Hypertension  Vifor International : Chronic Heart Failure, Hypertension  Bristol Myers Squibb : Chronic Heart Failure, Hypertension  Cytokinetics : Chronic Heart Failure, Hypertension</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Borioni Giuseppe	<b>2024</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Bristol Myers Squibb : Arrhythmias, General  Daiichi Sankyo : Atrial Fibrillation (AF)  Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>  Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine</p>
Bruining Nico	<b>2024</b>	Nothing to be declared
Capodanno Davide	<b>2024</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Terumo Inc : Interventional Cardiology  Sanofi Aventis : Interventional Cardiology  Sanofi Aventis : Pharmacology and Pharmacotherapy  Bristol Myers Squibb : Pharmacology and Pharmacotherapy  Novo Nordisk : Pharmacology and Pharmacotherapy</p>
Crea Filippo	<b>2024</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Novo-Nordisk : Acute Coronary Syndromes  <b>Receipt of royalties for intellectual property.</b>  Wolters Kluwer : Acute Coronary Syndromes  Edra SPA - Masson : Acute Coronary Syndromes</p>
Ferrari Roberto	<b>2024</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Servier : Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention  Lupin : Chronic Heart Failure , Acute Heart Failure , Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Acute Coronary Syndromes , Hypertension , Risk Factors and Prevention  Sunpharma : Chronic Heart Failure , Acute Heart Failure , Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Acute Coronary Syndromes , Hypertension , Risk Factors and Prevention  Merck Serono : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension, Risk Factors and Prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ferrari Roberto	<p><b>2024</b></p> <p><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension, Risk Factors and Prevention - Medical Trials Analysis, Fondazione Anna Maria Sechi per il Cuore (FASC), Art Research and Science Srl (A.R.S.1)</p> <p><b>Employment (including part time) in healthcare industry.</b> Medical Trials Analysis : Scientific Director</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b> Heart Failure Association</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Director of Art Research and Science Srl (A.R.S.1)</p>
Gerber Bernhard Lothar Marie	<p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Bristol Myers Squibb : Myocardial Disease Novartis : Risk Factors and Prevention</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b> Belgian Alliance for Cardiovascular Health (BACH)</p>
Gimelli Alessia	<p><b>2024</b></p> <p>Nothing to be declared</p>
Guzik Tomasz	<p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Moderna : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Chair; British Atherosclerosis Society</p>
Moons Philip	<p><b>2024</b></p> <p>Nothing to be declared</p>
Piepoli Massimo Francesco	<p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Novo Nordisk : Cardiovascular Disease in Special Populations Boehringer Ingelheim : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Menarini, : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b>  Medical Research Agency  <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Pharmacosmos : Chronic Heart Failure  Astra Zeneca : Chronic Heart Failure, Acute Heart Failure  Bayer : Chronic Heart Failure, Acute Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure  Novartis : Chronic Heart Failure, Acute Heart Failure  Pfizer : Chronic Heart Failure, Acute Heart Failure  Servier : Chronic Heart Failure, Acute Heart Failure  Vifor International : Chronic Heart Failure, Acute Heart Failure  Abbott Vascular : Chronic Heart Failure, Acute Heart Failure  Novo-Nordisk : Chronic Heart Failure, Acute Heart Failure</p>
Sommer Philipp	<p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b>  Fresenius Stiftung  <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Edwards Lifesciences : Arrhythmias, General  Medtronic : Arrhythmias, General  Abbott : Atrial Fibrillation (AF)  Boston Scientific : Atrial Fibrillation (AF)  Johnson &amp; Johnson : Atrial Fibrillation (AF)  <b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b>  Member of DGK, HRS, EHRA, ESC</p>
Vranckx Pascal	<p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  CSL Behring : Acute Coronary Syndromes  Janssen-Bristol Myers Squibb alliance : Acute Coronary Syndromes</p>